Kronos has downsized twice in the past year, firing 19% of its staff in November 2023 and then a further 21% in March 2024. Image
Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured loan facility with Oxford Finance. Image
Neurotech’s NT-501 implant contains allogeneic retinal pigment epithelium (RPE) cells that produce therapeutic proteins and ciliary neurotrophic factor (CNTF) for targeted and continuous treatment. Image
Tezspire is a thymic stromal lymphopoietin (TSLP) inhibiting monoclonal antibody, which generated $86m in sales in 2023. Image credit: eamesBot / Shutterstock. AstraZeneca and Amgen
DBV reported cash reserves of $46.4m as of 30 September, down by $92.2m it had at the end of last year. Image credit: UncleFredDesign /
Intra-Cellular expects Caplyta to rake in about $665-685m in sales this year. Image credit: Lightspring / Shutterstock. Having raised the full-year sales guidance for Caplyta
The merged company plans to focus on NLS’s Dual Orexin Agonist (DOA) platform and Kadimastem’s allogenic cell therapy program. Image credit: Lightspring / Shutterstock. Switzerland-based
Lexicon’s Zynquista is an oral dual inhibitor of the sodium-dependent glucose co-transporter types 1 and 2 (SGLT1 and SGLT2), which play a role in glucose
Matinas BioPharma first reported in August that it had signed a non-binding term sheet for global licensing rights to MAT2203 for all future treatment indications.
Spero’s SPR729 is a prodrug that converts into an active form that targets ATPase site of DNA gyrase B in mycobacteria. Image credit: Lemonsoup14 /